Inclusion Criteria:  18-55 years of age Ability to provide written consent Weight 50-110 kg with BMI 18.5-32 kg/m2 Willingness to use contraceptives Negative COVID-19 test Negative results for alcohol and drugs of abuse  Exclusion Criteria:  Pregnant or lactating females Familial bleeding disorder or individual or family history of bleeding diathesis or coagulopathy Females with active menstruation on day of dosing Use of prescription medications known to affect platelet function Use of NSAIDs, aspirin, anti-platelet or anti-coagulation therapy within 10 days of dosing Contraindication to anticoagulation or increased bleeding risks History of thrombocytosis, high platelet count, intracranial bleeding, aneurysm, stroke, vascular disease History of peptic ulcer disease, gastrointestinal or genitourinary bleed, severe trauma, fracture, major surgery of biopsy of parenchymal organ within past 3 months Planned surgery during the study Any clinical significant abnormality at screening Use of investigational drug in past 30 days or 5 half lives Concurrent enrollment in another clinical study or more than 3 clinical studies in past 12 months Any prior history of substance abuse or treatment or positive urine screen for drugs of abuse or positive breathalyzer test